Research Reports

Prepared Highlights

Membership: Medicare Advantage (MA) year-end 2025: 511,000; ACO REACH: 114,000. 2026 guidance: MA ~430,000 (incl. ~25,000 in care coordination fee model), ACO ~103,000 (midpoint), total platform 525,000–540,000 (prepared).
Revenue: Q4 2025: $1.57B; FY2025: $5.93B. FY2026 guidance: $5.41B–$5.58B (prepared).
Medical margin: Q4 2025: –$74M; FY2025: –$57M (includes –$60M exited markets, –$53M prior-year development). FY2026 guidance: $300M–$350M (prepared).
Adjusted EBITDA: Q4 2025: –$142M; FY2025: –$296M. FY2026 guidance: –$15M to +$15M (breakeven at midpoint) (prepared).
ACO REACH: Q4 2025 adjusted EBITDA: –$6M; FY2025: $41M. 2026 outlook: $20M–$25M contribution (prepared).
Cost trend: FY2025 full-year ~6.5% (Q4 booked at 7.4%, Q3 at 7.2%). 2026 assumption: gross 7.5%, net 7% (after 50bp payer benefit) (CFO).
Risk adjustment / BOI: Enhanced data pipeline covers >85% members with 99%+ correlation rate; net 40bp year-over-year improvement expected in 2026 (CFO).
Operating cost reductions: $35M in cost cuts executed, exceeding prior target (CFO).
Cash: Year-end 2025 cash & marketable securities $285M + $91M off-balance sheet ACO cash; 2026 year-end cash expected ≥$125M (CFO).
Part D exposure: Reduced to <15% of membership (CFO).
Quality: Composite star rating of 4.2; quality incentive opportunity expected to more than double in 2026 (CEO).
Heart failure pathways: Active programs adopted in >90% of network (CEO).
Guidance: Full-year 2026 revenue $5.41B–$5.58B; medical margin $300M–$350M; adj. EBITDA –$15M to +$15M; MA membership ~430,000; ACO ~103,000 (prepared).

Mgmt quotes

“2025 was a year for building the foundation of sustainable performance through intense focus on operational discipline.” (CEO)
“We executed on $35 million in operating cost reductions above what we communicated at the end of the third quarter.” (CFO)
“Our network consistently delivers quality performance for measures we can influence and control ahead of benchmarks at 4.2 stars on a composite basis.” (CEO)
“We expect 2026 to mark a strong improvement in medical margin and adjusted EBITDA supported by renegotiating with health insurers.” (CEO)
“We believe our BOI and clinical pathway initiatives will help mitigate the impact of the risk model revision and normalization factor outlined in the advanced notice.” (CFO)

Prepared Metrics

Metric	Value	Speaker/Context
MA membership year-end 2025	511,000	CFO
ACO REACH membership year-end 2025	114,000	CFO
FY2025 total revenue	$5.93B	CFO
Q4 2025 revenue	$1.57B	CFO
FY2025 medical margin	–$57M	CFO
FY2025 adjusted EBITDA	–$296M	CFO
FY2025 cost trend (full year)	~6.5%	CFO
FY2026 revenue guidance	$5.41B–$5.58B	CFO
FY2026 medical margin guidance	$300M–$350M	CFO
FY2026 adj. EBITDA guidance	–$15M to +$15M	CFO
FY2026 MA membership guidance	~430,000 (incl. 25k care coord.)	CFO
FY2026 ACO membership guidance	~103,000	CFO
FY2026 gross cost trend assumption	7.5%	CFO
FY2026 net cost trend assumption	7%	CFO
Year-end cash (Dec 2025)	$285M + $91M ACO	CFO
Cash target end-2026	≥$125M	CFO
Quality star composite rating	4.2	CEO
Heart failure pathway adoption	>90% of network	CEO
Part D exposure	<15% of membership	CFO

Q&A Batch (1-5 of 9)

Q1 — Jack Slevin

Topic: 2025成本趋势修正及2027年MA/ACO策略
Key points:
- 2025年Q3成本趋势从低6%升至7.2%，因住院量激增（含约650万美元超百万美元病例）
- Q4成本趋势上调至7.4%，全年成本趋势从低-中5%升至6.5%
- 2027年将继续通过合同调整、疾病负担计划及费率通知结果改善利润率
- ACO REACH新模型为10年期，提供长期规划基础，但需更多政策透明
Mgmt stance: 中性偏谨慎 – 因有限索赔可见性而主动上调趋势，强调持续执行现有杠杆但需观察成本走向

Q2 — Jailendra Singh

Topic: 住院成本集中度与OpEx成本削减机会
Key points:
- Q3住院成本上升并非集中于特定市场，9月为季度内最高
- Q4成本趋势7.4%是基于有限数据作出的谨慎决定，以提供2026年良好起点
- 2026年OpEx成本削减35亿美元（原文为$35 million，注意单位），来源包括自动化、AI及技术
- 管理层表示尚未停止寻找更多成本优化机会，但后续目标实现难度更大
Mgmt stance: 中性偏积极 – 对现有成本削减成果有信心，同时承认后续需依赖技术但持续探索

Q3 — Hua Ha

Topic: ACO REACH中的FSS趋势与MA费率通知影响
Key points:
- 2025年MA成本趋势上半年为中5%，Q3明显加速；ACO REACH中的FSS趋势从8.5%降至8.1%
- Q3成本趋势偏高，与市场认为下半年趋势放缓的观点相反
- 对费率通知，管理层希望最终利率能反映近年成本趋势，并期待部分调整项（如皮肤亚组风险模型）能延迟或分散实施
Mgmt stance: 中性 – 承认成本加速现实，强调需平衡费率调整与成本动态，等待最终通知

Q4 — Ryan Langston

Topic: 团体MA业务占比及利润率恢复
Key points:
- 2025年中团体MA占比约17%-18%，预计2026年占比不会有显著变化
- 最终成员数据需等到Q1末，目前无法确定具体影响
Mgmt stance: 中性 – 过早判断，暂无重大变化预期

Q5 — Matthew Shea

Topic: 质量相关利润率机会及2026年翻倍潜力
Key points:
- 2025年质量激励目标约2500万美元，预计接近达成
- 2026年质量相关机会翻倍，源自星级提升（2024年约4.2星，2025年有改善但需最终数据）
- 2026年指引中未计入该翻倍收益，仅基于2025年类似表现；管理层实际目标更高
Mgmt stance: 中性偏积极 – 对2025年表现有信心，2026年机会存在但未完全反映在指引中，有上行潜力

Q&A Batch (6-9 of 9)

Q6 — Stephen Baxter

Topic: CMS risk model changes & medical margin bridge decomposition
Key points:
- Company is exposed to the 330 bps normalization item in the CMS announcement, but has historically offset V28 implementation (~3 %–3.5 % per year) and expects to do so again in 2027.
- Clinical pathways (e.g., congestive heart failure at ~90 % platform implementation) and additional pathways are key offsets; management acknowledges need to “step up” for 2027.
- Medical margin bridge: the $127 million from payer contracts is primarily from percent-of-premium changes or relief from payer stars issues — already contracted and “locked in” for 2026.
Mgmt stance: bullish — confident in ability to offset risk model headwinds via clinical execution and existing contracts.

Q7 — Wenji Li

Topic: Special needs plan (SNP) exposure and mix shift
Key points:
- Current SNP membership is ~7 % of total; no sufficient data yet to determine a meaningful mix shift.
- No structural margin opportunity commentary provided.
Mgmt stance: neutral — insufficient information to assess direction.

Q8 — Justin Lake

Topic: Membership exits / recontracting & cost trend disconnect with CMS
Key points:
- Membership exits are payer- and market-specific, not concentrated in one or two payers; economics differed across payers/markets in 2026 renewals.
- Company “couldn’t get to a deal this year” but leaves open future contracts if economics and risk align; same lens applies to 2027 renewals.
- Industry and company agree there is a “disconnect” between bottom-line rates paid and observed cost trends (fee-for-service + ACO REACH); no current bridge to close the gap.
Mgmt stance: cautious — firm on requiring proper compensation; industry advocating for CMS rate notice revisit.

Q9 — Craig Jones (followed by Daniel Grosslight/Luismario Higuera)

Topic: Chart review impact & new geography entry costs
Key points:
- Removal of selected/unlinked diagnoses is “minimal” due to model alignment with primary care physicians (members seen in office, few unlinked conditions); impact is broad-based across payers.
- Part C risk model changes vary by market, not uniform.
- The $15 million new geography entry cost in guidance is driven by capital commitments from prior growth, some carryover from previous years, and “a little bit of growth this year”.
Mgmt stance: neutral to cautious — chart review minimal by design; growth costs are backward-looking legacy commitments.